Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a clinical-stage biopharmaceutical company specializing in the discovery, research, and development of next-generation biologic drugs and novel oncology therapeutics. The company's proprietary drug development platforms include PolyXen™, which enhances the half-life and other pharmacological properties of biologic drugs.
Xenetic’s lead investigational product candidates comprise the FDA orphan-designated oncology therapeutic Sodium Cridanimod for progesterone receptor-negative endometrial cancer, and a polysialylated form of erythropoietin for treating anemia in pre-dialysis patients with chronic kidney disease. Xenetic is also collaborating with Shire PLC (formerly Baxalta, Baxter Incorporated, and Baxter Healthcare) to develop polysialylated blood coagulation factors, including a next-generation Factor VIII.
In the immune-oncology space, Xenetic is advancing XCART, a personalized CAR T platform technology, and the DNase platform aimed at improving existing treatments by targeting neutrophil extracellular traps (NETs) implicated in cancer progression and resistance. The company is working towards Phase 1 clinical development for pancreatic carcinoma and other solid tumors.
Recent financial updates reveal that Xenetic ended Q2 2023 with approximately $10.7 million in cash and no debt. The company reported a net loss of $1.1 million for Q3 2023 and continued to secure strategic collaborations and advance its DNase-based oncology program.
Xenetic Biosciences (NASDAQ: XBIO) reported its financial results for Q1 2021, showing a net loss of approximately $1.3 million. The company is advancing its XCART platform, a personalized CAR T therapy targeting B-cell lymphomas, with an exploratory patient biopsy trial initiated in Eastern Europe. Additionally, royalty payments of $0.2 million were received from Takeda under an exclusive license agreement. Research and development expenses increased by 75.1% to $0.6 million due to XCART investments, while working capital decreased by $1.2 million to approximately $10.2 million.
Xenetic Biosciences (NASDAQ: XBIO) announced that CEO Jeffrey Eisenberg will present at the Q2 Virtual Investor Summit on May 18, 2021, at 3:30 PM ET. The event will include a live video webcast accessible on the company's IR Calendar page and will be archived for 90 days. Xenetic focuses on advancing its XCART™ personalized CAR T platform, targeting patient-specific neoantigens for B-cell lymphomas. The company also leverages its PolyXen® drug delivery platform and holds an exclusive agreement with Takeda Pharmaceuticals.
Xenetic Biosciences (NASDAQ: XBIO) announced approval for an exploratory study of its XCART platform to target Non-Hodgkin lymphoma (NHL) patients in Eastern Europe. The study aims to refine the process of neoantigen identification and CAR T candidate generation. Conducted at the Vitebsk Regional Clinical Oncological Center in Belarus, it will enroll adult B-Cell NHL patients, enabling further development of autologous CAR T-Cells. Collaborations with Scripps Research and PJSC Pharmsynthez are instrumental in advancing XCART technology, paving the way for future IND-enabling studies in the U.S.
Xenetic Biosciences (NASDAQ: XBIO) reported its 2020 financial results, highlighting advancements in its XCART™ platform aimed at targeting tumor-specific antigens, with a focus on B-cell lymphomas, representing a market opportunity exceeding $5 billion annually. The company reduced its R&D expenses to $1.7 million from $4.9 million in 2019. The net loss for 2020 was approximately $10.9 million, with cash reserves of $11.5 million. Recent partnerships aim to enhance XCART development, and the company anticipates key milestones including an exploratory study in Eastern Europe and regulatory meetings.
Xenetic Biosciences (NASDAQ: XBIO), a biopharmaceutical company, announced on March 3, 2021 that its CEO, Jeffrey Eisenberg, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The company focuses on advancing its XCART™ technology, designed to target specific neoantigens in tumors. A video presentation will be available on-demand starting March 9, 2021, at 7:00 AM ET. Xenetic is known for developing personalized CAR T therapies for B-cell lymphomas and utilizing its PolyXen® platform to enhance drug delivery.
Xenetic Biosciences (NASDAQ: XBIO) announced that its partner, PJSC Pharmsynthez, has filed a registration dossier for Epolong in Russia to treat anemia in chronic kidney disease patients. This follows positive Phase 3 clinical trial data demonstrating Epolong's efficacy. The collaboration utilizes Xenetic's PolyXen technology to enhance Epolong's pharmacological properties. If approved, Epolong would be the first product using PolyXen, with production expected to begin in Q1 2022. Pharmsynthez aims to complete registration by the end of 2021.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced that its CEO, Jeffrey Eisenberg, will present at NobleCon17 on January 19, 2021, at 9:45 AM ET. The virtual conference is free to attend and will feature a high-definition video webcast of the presentation.
The company focuses on advancing XCART, a personalized CAR T platform targeting tumor-specific neoantigens for treating B-cell lymphomas. Additionally, Xenetic utilizes its proprietary PolyXen drug delivery platform to enhance biologic drugs, in partnership with other biotech firms.
Xenetic Biosciences (NASDAQ:XBIO) announced its participation in the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2021. CEO Jeffrey Eisenberg will present during a fireside chat, with a video webcast available for on-demand viewing starting January 11 at 6:00 AM ET. The company focuses on advancing its XCART™ personalized CAR T platform targeting tumor-specific neoantigens, and it leverages its PolyXen® drug delivery platform for biotech partnerships.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced the closing of a registered direct offering on December 14, 2020, selling 2,448,980 shares at $2.45 each, generating approximately $6.0 million in gross proceeds. The funds will be allocated to general corporate purposes and the advancement of the proprietary XCART technology for treating B-cell Non-Hodgkin lymphomas. The offering was conducted under a shelf registration statement with H.C. Wainwright & Co. serving as the exclusive placement agent.
Xenetic Biosciences (NASDAQ: XBIO) announced a registered direct offering of 2,448,980 shares at $2.45 each, aiming for gross proceeds of approximately $6.0 million. The funds will support general corporate purposes and the advancement of the XCART platform, focusing on personalized CAR T therapies for B-cell Non-Hodgkin lymphomas. The offering is expected to close around December 14, 2020. H.C. Wainwright & Co. is the exclusive placement agent for this transaction.
FAQ
What is the current stock price of Xenetic Biosciences (XBIO)?
What is the market cap of Xenetic Biosciences (XBIO)?
What is Xenetic Biosciences' main focus?
What are the primary platforms used by Xenetic Biosciences?
What are Xenetic Biosciences' lead investigational products?
Who are Xenetic Biosciences' key partners?
What is the focus of Xenetic's DNase platform?
What are the company's recent financial highlights?
What is the goal of Xenetic's XCART technology?
What are the company’s plans for its DNase-based oncology program?
How does the PolyXen™ platform benefit biologic drugs?
Where can I find more information about Xenetic Biosciences?
